Chapter 2
Increased Kidney Metabolism as a Pathway to Kidney Tissue Hypoxia and Damage: Effects of Triiodothyronine and Dinitrophenol in Normoglycemic Rats

Malou Friederich-Persson, Patrik Persson, Angelica Fasching, Peter Hansell, Lina Nordquist, and Fredrik Palm

Abstract Intrarenal tissue hypoxia is an acknowledged common pathway to end-stage renal disease in clinically common conditions associated with development of chronic kidney disease, such as diabetes and hypertension. In diabetic kidneys, increased oxygen metabolism mediated by mitochondrial uncoupling results in decreased kidney oxygen tension (PO$_2$) and contributes to the development of diabetic nephropathy. The present study investigated whether increased intrarenal oxygen metabolism per se can cause intrarenal tissue hypoxia and kidney damage, independently of confounding factors such as hyperglycemia and oxidative stress. Male Sprague–Dawley rats were untreated or treated with either triiodothyronine (T$_3$, 10 g/kg bw/day, subcutaneously for 10 days) or the mitochondria uncoupler dinitrophenol (DNP, 30 mg/kg bw/day, oral gavage for 14 days), after which in vivo kidney function was evaluated in terms of glomerular filtration rate (GFR, inulin clearance), renal blood flow (RBF, Transonic, PAH clearance), cortical PO$_2$ (Clark-type electrodes), kidney oxygen consumption (QO$_2$), and proteinuria. Administration of both T$_3$ and DNP increased kidney QO$_2$ and decreased PO$_2$ which resulted in proteinuria. However, GFR and RBF were unaltered by either treatment. The present study demonstrates that increased kidney metabolism per se can cause intrarenal tissue hypoxia which results in proteinuria. Increased kidney QO$_2$ and concomitantly reduced PO$_2$ may therefore be a mechanism for the development of chronic kidney disease and progression to end-stage renal disease.
2.1 Introduction

Increased kidney oxygen consumption (QO\textsubscript{2}) may result in decreased kidney tissue oxygen tension (PO\textsubscript{2}), ultimately resulting in kidney damage. Importantly, intrarenal kidney tissue hypoxia is a proposed pathway to chronic kidney disease and end-stage renal disease in conditions such as diabetes and hypertension \[1, 2\]. To increase kidney QO\textsubscript{2}, healthy rats were treated with either dinitrophenol (DNP) or triiodothyronine (T\textsubscript{3}). DNP is a chemical uncoupler of mitochondria \[3\]. By decreasing the mitochondria membrane potential, the process of mitochondria uncoupling reduces formation of oxidative stress but increases mitochondria QO\textsubscript{2} \[4\]. Through the nuclear receptor superfamily, T\textsubscript{3} controls gene transcription and results in increased QO\textsubscript{2}, mainly via mitochondrial pathways \[5\]. By utilizing DNP and T\textsubscript{3}, we create two independent models of increased kidney QO\textsubscript{2} to investigate whether increased QO\textsubscript{2} per se can cause intrarenal tissue hypoxia and kidney damage.

2.2 Materials and Methods

All animal procedures were carried out according to the National Institutes of Health guidelines and approved by the local animal ethics committee. Normoglycemic male Sprague–Dawley rats (Charles River, Sulzfeld, Germany) received either no treatment, DNP administration (30 mg/kg bw dissolved in 1.5 % methyl cellulose) by oral gavage for 14 days or T\textsubscript{3} (10 \(\mu\)g/kg bw/day) administered for 10 days by surgically implanted osmotic minipumps (Alzet Company, Cupertino, CA, USA). The animals receiving T\textsubscript{3} were simultaneously treated with candesartan (1 mg/kg bw in drinking water) in order to minimize the influence of thyroid hormone-induced renin release.

Animals were sedated with sodium thiobutabarbital (Inactin, 120 mg/kg bw i.p.) and placed on a servo-rectally controlled heating pad to maintain body temperature at 37 °C. Tracheotomy was performed to facilitate breathing, and polyethylene catheters were placed in the carotid artery and femoral vein to allow monitoring of mean arterial pressure (MAP, Statham P23dB, Statham Laboratories, Los Angeles, CA, USA), blood sampling, and infusion of saline (5 ml/kg bw/h). The left kidney was exposed by a subcostal flank incision and immobilized in a plastic cup. The left ureter and bladder were catheterized to allow for timed urine sampling and urinary drainage, respectively. After surgery, the animal was allowed to recover for 30 min followed by a 40-min experimental period at the end of which a blood sample was carefully collected from the renal vein in order to calculate arteriovenous differences.

Kidney cortex PO\textsubscript{2} was measured using Clark-type oxygen electrodes (Unisense, Aarhus, Denmark). Glomerular filtration rate (GFR) was measured by clearance of \(^{3}\text{H}\)-inulin (185 kBq bolus followed by 185 kBq/kg bw/h; American Radiolabeled Chemicals, St Louis, MO, USA). Renal blood flow (RBF) was measured by Transonic flow probe (Transonic Systems Inc., Ithaca, NY, USA) or clearance by
C-para-aminohippuric acid (PAH, 185 kBq bolus followed by 185 kBq/kg bw/h; American Radiolabeled Chemicals). GFR was calculated as inulin clearance = ([inulin]_urine * urine flow)/[inulin]_plasma and RBF with PAH clearance corrected for PAH extraction and the hematocrit. Total kidney QO₂ (µmol/min) was estimated from the arteriovenous difference in O₂ content (O₂_{ct} = ([hemoglobin]*oxygen saturation*1.34 + PO₂*0.003)) *total RBF. Tubular Na⁺ transport (T_{Na⁺}, µmol/min) was calculated as follows: T_{Na⁺} = [P_{Na⁺}]*GFR, where [P_{Na⁺}] is plasma Na⁺ concentration. T_{Na⁺} per QO₂ was calculated as T_{Na⁺}/QO₂.

Statistical comparisons were performed using one-way analysis of variance with Dunnett’s post hoc test. *p < 0.05 was considered significant and all values are presented as mean ± SEM.

2.3 Results

A decreased body weight and increased kidney weight was observed in T₃-treated animals compared to controls. GFR, MAP, RBF, Na⁺-excretion, and urinary flow rates were unaffected in both treated groups (Table 2.1). DNP and T₃ administration resulted in increased kidney QO₂ (Fig. 2.1) and decreased intrarenal kidney PO₂ (Fig. 2.2) compared to no treatment. Importantly, the reduced PO₂ resulted in increased proteinuria in both DNP and T₃-treated animals (Fig. 2.3).

Table 2.1 Systemic and kidney-specific parameters in control animals receiving either no treatment, dinitrophenol for 14 days, or triiodothyronine for 10 days

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Dinitrophenol</th>
<th>Triiodothyronine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>399 ± 10</td>
<td>399 ± 7</td>
<td>350 ± 7*</td>
</tr>
<tr>
<td>Kidney weight (g)</td>
<td>1.4 ± 0.1</td>
<td>1.4 ± 0.0</td>
<td>2.7 ± 0.1*</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>107 ± 2</td>
<td>108 ± 7</td>
<td>97 ± 4</td>
</tr>
<tr>
<td>Urine flow (µl/min)</td>
<td>3.2 ± 0.8</td>
<td>4.1 ± 0.8</td>
<td>4.4 ± 0.6</td>
</tr>
<tr>
<td>Renal blood flow (ml/min)</td>
<td>11.1 ± 0.7</td>
<td>11.4 ± 1.1</td>
<td>8.1 ± 1.3</td>
</tr>
<tr>
<td>Glomerular filtration rate (µmol/min)</td>
<td>1.6 ± 0.2</td>
<td>2.1 ± 0.3</td>
<td>1.8 ± 0.3</td>
</tr>
<tr>
<td>Sodium excretion (µmol/min)</td>
<td>0.1 ± 0.1</td>
<td>0.2 ± 0.1</td>
<td>0.2 ± 0.2</td>
</tr>
</tbody>
</table>

*Denotes *p* < 0.05 versus control animals

![Fig. 2.1](image1.png) Kidney oxygen consumption in control animals receiving either no treatment, dinitrophenol for 14 days, or triiodothyronine for 10 days. * denotes *p* < 0.05 versus control
2.4 Discussion

In the present study, administration of DNP and T₃ to normoglycemic rats increased kidney QO₂, decreased kidney PO₂, and increased proteinuria, demonstrating that increased kidney QO₂ is a pathway to kidney damage. Interestingly, treatment with DNP in patients has resulted in proteinuria [6, 7] and patients with untreated Grave’s disease also develop proteinuria [8]. It may be argued that DNP is directly nephrotoxic as it is a known environmental toxin. However, this argument cannot apply to T₃ as it is an endogenous hormone. The use of T₃ to establish intrarenal hypoxia verifies that increased kidney QO₂ indeed ultimately results in kidney damage. As T₃ is known to affect the renal angiotensin system and cause hypertension [9], these animals were simultaneously treated with candesartan. It is also unlikely that the observed kidney damage is a result of ATP shortage rather than limited availability of oxygen as the Na⁺ excretion is unchanged in both DNP and T₃-treated animals.
a finding supported by others [10]. We propose that the mechanism to kidney damage is decreased kidney PO$_2$ resulting in intrarenal tissue hypoxia, leading to development of proteinuria.

In 1998, it was originally proposed by Fine et al., that the limitation of intrarenal oxygen availability is the key mechanism initiating kidney damage [11]. Since then, this theory has received considerable support, and intrarenal hypoxia is now an acknowledged pathway to chronic kidney disease and end-stage renal disease [1, 2, 12–14]. The oxygen level in the kidney is important because an increased RBF will increase the workload and, therefore, the kidney QO$_2$. This makes increased RBF a very inefficient way to increase renal PO$_2$, and the kidney is therefore vulnerable to alterations in either QO$_2$ or oxygen availability. This is further supported by studies reporting that Navajo Indians living at high altitude have increased incidence of end-stage renal disease compared to their corresponding control group at sea level [15]. Also, type 2 diabetic patients at high altitude have increased incidence of diabetic nephropathy despite similar blood pressure and metabolic parameters [16].

In the present study, the utilization of two independent models to create intrarenal tissue hypoxia both resulted in kidney damage evident as increased urinary protein leakage. This clearly demonstrated the importance of intrarenal PO$_2$ in maintaining normal kidney function.

References

Oxygen Transport to Tissue XXXV
2013, XXX, 507 p. 170 illus., Hardcover
ISBN: 978-1-4614-7256-8